A Study of Mavacamten in Obstructive Hypertrophic Cardiomyopathy
Completed · Phase 3 · NCT05414175
Conditions: Cardiomyopathy, Hypertrophic Obstructive
At a glance
- Research payments reported, 2025
- $10,545
- U.S. investigators named
- 1
- Sites paid
- 1
- Planned or actual enrollment
- 38
About the trial
- Sponsor
- Bristol-Myers Squibb
- Tested
- Mavacamten (drug)
- Dates
- Started 2022-08-19; completion 2025-12-11
- Results posted
- Yes
The purpose of this study is to evaluate the effectiveness, safety, and tolerability of a 30-week course of mavacamten and the long-term effects of mavacamten in Japanese participants with symptomatic obstructive hypertrophic cardiomyopathy (HCM).
From ClinicalTrials.gov, last updated 2026-01-27. Full record, eligibility and contacts (opens in a new tab)
Industry funding
E.r. Squibb & Sons, L.l.c. reported $10,545 in research payments for this study in 2025 (2 payments).
Products named: Camzyos
Research payments usually go to hospitals, universities and research sites to run a study, not to the investigators personally. A payment is not evidence of wrongdoing.
U.S. investigators named on this study
Clinicians the company named as principal investigators in its Open Payments reports.
Sites paid to run it
- Jordan B Strom, Llc $8,945
- $1,600
Sources: CMS Open Payments research payments (program year 2025) and ClinicalTrials.gov, U.S. National Library of Medicine.